BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
See today's BioWorld
See today's BioWorld Asia
Home
» Immunotherapy company Arbele banking on cadherin-17 as target for gastrointestinal cancers
To read the full story,
subscribe
or
sign in
.
Newco news
Immunotherapy company Arbele banking on cadherin-17 as target for gastrointestinal cancers
Oct. 10, 2023
By
Tamra Sami
No Comments
Arbele Ltd. founder and CEO John Luk identified and patented cadherin-17 as a therapeutic cancer target, and the company was founded to develop immunotherapies for gastrointestinal cancers, which are prevalent in Asia Pacific.
BioWorld
BioWorld Asia
Newco news
Cancer
Australia
China
